Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
January 16, 2024
NRX-101 has demonstrated potent activity against resistant urinary pathogens upon FDA review QIDP designation grants Priority Review and an additional 5 years of additional product exclusivity 3...
-
January 2, 2024
The benefits of ketamine are clear, but so are the risks Ketamine has now demonstrated clear superiority to placebo and non-inferiority to electroshock therapy in randomized trials encompassing...
-
January 2, 2024
Company to present full compliance plan, based on achieving clinical milestones, to Nasdaq on January 4, 2024 RADNOR, Pa., Jan. 2, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)...
-
December 27, 2023
Former Inspector General, US Dept. of Health and Human Services Former Assistant US Attorney for the Eastern District of Virginia Nationally recognized attorney in highly regulated industries;...
-
December 19, 2023
Ketamine, an NMDA blocker, was highly effective compared to active comparator in rapidly reducing Suicidality (p=0.0003) This study represents the second well-controlled trial NRx has licensed...
Click here to view our corporate presentation or on the image below